

August 2026

ACR Update

The ACR team would like to welcome our newest coordinator, Austin, to the team!



Did You Know?

Every medication you use today was tested in clinical trials before becoming available to the public, helping ensure it is safe and effective. Before they reach your doctor or pharmacy, they undergo years of carefully monitored research to assess their safety and efficacy.



August 2026

Enrolling Trials

(Click on each study name for more info!)

Dry Age-Related Macular Degeneration (AMD)

[Sanofi DFI18231](#)

[Character Biosciences CTX114](#)

Wet Age-Related Macular Degeneration (AMD)

[Hoffman-La Roche GR40549](#)

[Abbvie ABBV-RGX-314](#)

[Adverum ADVM-022-13 AQUARIUS](#)

Diabetic Macular Edema (DME)

[Genentech GR46431](#)

[Boehringer-Ingelheim 1485-0018 Thulite](#) (oral agent)

[Boehringer Ingelheim 1523-0001](#)

[Study Spotlight](#)

Abbvie ABBV-RGX-314

A phase 3b study evaluating a single administration of gene therapy compared to standard of care injections for patients with Wet Age-related Macular Degeneration (Wet AMD). Typical treatment plans for Wet AMD require injections every 4-16 weeks. Gene therapy is being evaluated as an alternative solution to potentially reduce or eliminate the current treatment burden that often leads to undertreatment and vision loss.

[Click here for more information](#)